Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.70 |
| ▸ | TAAR1 | Q96RJ0 | 7/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.52 |
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8508448 | 0.98 | HRH3 (0.67) | HRH3TAAR1KCNH2CYP1A2CYP2A6 | |
| Hydrochloric Acid SCHEMBL28340007 | 0.95 | HRH3 (0.64) | HRH3TAAR1KCNH2CYP1A2CYP2A6 | |
| SCHEMBL18762839 | 0.89 | HRH3 (0.84) | HRH3TAAR1KCNH2CYP1A2CHRNA7 | |
| SCHEMBL19146986 | 0.86 | SIGMAR1 (0.55) | HRH3TAAR1KCNH2CYP1A2CYP2A6 | |
| SCHEMBL9280499 | 0.84 | SIGMAR1 (0.64) | HRH3TAAR1KCNH2CYP1A2CYP2A6 | |
| Water SCHEMBL11573228 | 0.81 | SIGMAR1 (0.66) | HRH3KCNH2 | |
| Hydrochloric Acid SCHEMBL11616768 | 0.81 | SIGMAR1 (0.66) | HRH3KCNH2 | |
| SCHEMBL1975214 | 0.80 | HRH3 (0.70) | HRH3TAAR1KCNH2CHRNA7 | |
| SCHEMBL3059072 | 0.80 | HRH3 (0.70) | HRH3TAAR1KCNH2CHRNA7 | |
| SCHEMBL3057063 | 0.80 | HRH3 (0.70) | HRH3TAAR1KCNH2CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230301984-A1 | CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-09-28 | — | — | US | disclosed |
| WO-2021254389-A1 | PYRAZOLO[3,4-D]PYRIMIDINE-3-KETONE DERIVATIVE AS WEE-1 INHIBITOR | 微境生物医药科技(上海)有限公司 | 2021-12-23 | — | — | WO | disclosed |
| EP-3825312-A1 | INTERMEDIATES FOR PREPARING INHIBITORS OF HEPATITIS C VIRUS | Gilead Pharmasset LLC (US) | 2021-05-26 | — | — | EP | disclosed |
| US-10370356-B2 | Pyridinone dicarboxamide for use as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2019-08-06 | — | — | US | disclosed |
| US-20170312363-A1 | MULTIFUNCTIONALIZED POLYETHYLENE GLYCOL DERIVATIVE AND PREPARATION METHOD THEREFOR | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2017-11-02 | — | — | US | disclosed |
| US-RE46511-E1 | Fused pyrimidine derivatives for inhibition of tyrosine kinase activity | HANMI SCIENCE CO., LTD. (KR) | 2017-08-15 | — | — | US | disclosed |
| US-20170196862-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-07-13 | — | — | US | disclosed |
| EP-2476682-B1 | 8-OXODIHYDROPURINE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO LTD (JP) | 2017-04-26 | — | — | EP | disclosed |
| EP-2117531-B1 | COMBINATION TREATMENT OF SOLID CANCERS WITH ANTIMETABOLITES AND TYROSINE KINASE INHIBITORS | AB SCIENCE (FR) | 2016-11-02 | — | — | EP | disclosed |
| EP-2440554-B1 | PYRAZOLE OXADIAZOLE DERIVATIVES AS S1P1 AGONISTS | MERCK SERONO SA (CH) | 2016-10-05 | — | — | EP | disclosed |
| EP-1525200-B1 | 2-(3-AMINOARYL)AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITORS | AB SCIENCE (FR) | 2007-10-10 | — | — | EP | disclosed |
| US-20070225293-A1 | Use of C-Kit Inhibitors for Treating Fibrosis | AB SCIENCE | 2007-09-27 | — | — | US | disclosed |
| US-20070225293-A1 | Use of C-Kit Inhibitors for Treating Fibrosis | AB SCIENCE | 2007-09-27 | — | — | US | disclosed |
| US-20070191267-A1 | Use of tyrosine kinase inhibitors for treating cerebral ischemia | AB SCIENCE | 2007-08-16 | — | — | US | disclosed |
| US-20070191267-A1 | Use of tyrosine kinase inhibitors for treating cerebral ischemia | AB SCIENCE | 2007-08-16 | — | — | US | disclosed |
| US-20070099960-A1 | LXR receptor modulators | LABORATOIRES FOURNIER S.A. (FR) | 2007-05-03 | — | — | US | disclosed |
| US-20070099960-A1 | LXR receptor modulators | LABORATOIRES FOURNIER S.A. (FR) | 2007-05-03 | — | — | US | disclosed |
| WO-2007026251-A2 | USE OF DUAL C-KIT/FGFR3 INHIBITORS FOR TREATING MULTIPLE MYELOMA | AB SCIENCE (FR) | 2007-03-08 | — | — | WO | disclosed |
| US-20070032521-A1 | Use of c-kit inhibitors for treating type II diabetes | AB SCIENCE | 2007-02-08 | — | — | US | disclosed |
| US-20070032521-A1 | Use of c-kit inhibitors for treating type II diabetes | AB SCIENCE | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10370356-B2 | Pyridinone dicarboxamide for use as bromodomain inhibitors | BRD4, BRD3, BRDT | HRH3 78/4885TAAR1 1352/4885KCNH2 1884/4885 |
| US-20070225293-A1 | Use of C-Kit Inhibitors for Treating Fibrosis | KIT, CPA3, CMA1 | HRH3 74/4885TAAR1 3781/4885KCNH2 1070/4885 |
| US-20070099960-A1 | LXR receptor modulators | NR1H2, NR1H3, PPARD | HRH3 1302/4885TAAR1 742/4885KCNH2 3441/4885 |
| US-20070032521-A1 | Use of c-kit inhibitors for treating type II diabetes | KIT, CPA3, CMA1 | HRH3 98/4885TAAR1 3688/4885KCNH2 243/4885 |
| US-20070191267-A1 | Use of tyrosine kinase inhibitors for treating cerebral ischemia | KIT, MAST3, CPA3 | HRH3 139/4885TAAR1 3193/4885KCNH2 1228/4885 |
| US-20230301984-A1 | CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION | ALDH1A2, PDE6D, PDE6C | HRH3 4467/4885TAAR1 2781/4885KCNH2 3092/4885 |
| US-20170196862-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | HRH3 2523/4885TAAR1 2181/4885KCNH2 64/4885 |
| US-20170312363-A1 | MULTIFUNCTIONALIZED POLYETHYLENE GLYCOL DERIVATIVE AND PREPARATION METHOD THEREFOR | HDGF, F11, F12 | HRH3 1666/4885TAAR1 3874/4885KCNH2 4045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.